Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of NS-065/NCNP-01 in patients with Duchenne muscular dystrophy
jRCT2080223236Phase 2
- Sponsor
- Nippon Shinyaku
- Start
- Jun 2016
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of viltolarsen in Duchenne muscular dystrophy (DMD), sponsored by Nippon Shinyaku.
02
Drugs
viltolarsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2080223236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223236.